Epigenetics Market Largest Regional Revenue Share in Near Future

Epigenetics has provided hope for advanced cancer treatment, and is expected to be the one of the most effective treatment options for diseases in future, especially cancer. The rise in awareness about epigenetic factors and their role in developmental & disease biology are anticipated to create lucrative opportunities in the forecast period.

Global Epigenetics Market was valued at $555 million in 2016, and is estimated to reach at $1,321 million by 2023, registering a CAGR of 13.1% from 2017 to 2023. Epigenetics is an extension of genetics and developmental biology, which involves study of cellular and physiological trait variations initiated by external or environmental stimuli. Epigenetics deals with changes in gene expression caused by certain base pairs in DNA & RNA, which are “turned off” or “turned on”, through chemical reactions contrary to being affected by changes in the nucleotide sequence. Epigenetic alterations result into change in phenotype, with the genotype of the organism being constant. Epigenetics changes are influenced by different factors, such as age, surrounding environment, lifestyle, disease state, and others.

Access Full Summary at : https://www.alliedmarketresearch.com/epigenetics-market

DNA methylation and histone modification for instance are epigenetic processes wherein the alteration in gene expression is observed without the change in the DNA sequence. Rise in cancer prevalence; improved funding & aids for R&D activities, surge in partnership between academic, pharmaceutical, and biotechnology companies, and increased application of epigenetics in non-oncology diseases are the key factors that propel the growth of this market.

The epigenetics market is segmented based on product, application, end user, and geography. Based on product, it is divided into enzymes, kits & assays, instruments, and, reagents. Enzymes are further classified into DNA ligases, DNA polymerases, other DNA-modifying enzymes, acetylases, methyltransferases, other protein-modifying enzymes, reverse transcriptase, RNA ligases, and other RNA-modifying enzymes. Kits & assays are further subdivided into bisulfite conversion kits, chip-seq kits, deep sequencing kits, methyltransferase assays, histone assays, immunoprecipitation kits, and other epigenetic kits. Based on instruments, the market is further sub segmented into mass spectrometers, next-generation sequencers, qPCRs, and sonicators & other instruments. Based on reagents, it is categorized into antibodies, buffers, histones, magnetic beads, primers, and other epigenetics reagents.

On the basis of application, the market is bifurcated into oncology and non-oncology. Oncology is further sub-segmented into solid tumors & liquid tumors and non-oncology is further categorized into inflammatory diseases, metabolic diseases, infectious diseases, cardiovascular diseases, developmental biology, drug discovery, and other applications. On the basis of end user, the market is classified into academic & research institutes, pharmaceutical companies, biotechnology companies & contract research organizations (CROs). Geographically, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Get Sample PDF Brochure at : https://www.alliedmarketresearch.com/request-sample/846

The market is expected to witness a moderate growth during the forecast period, owing to the rise in epigenetic drug discovery. Furthermore, surge in prevalence of cancer and technological advancements in epigenetics research are anticipated to augment the market growth. The untapped potential of emerging markets, such as China and India, is expected to present various opportunities for market expansion. However, high costs of instruments and dearth of skilled personnel are expected to hamper the market growth.
The report provides extensive competitive analysis and profiles of key market players, such as Abcam Plc., Illumina, QIAGEN N.V., Merck & Co., New England Biolabs, Inc., Epizyme Inc., Thermo Fisher Scientific, Inc., Active Motif. Diagenode, Inc., and Zymo Research Corporation.
The other players in the value chain include Domainex, CellCentric Ltd., Chroma Therapeutics Ltd., Eisai Co. Ltd., Novartis International AG, Oncolys Biopharma Inc., Syndax Pharmaceuticals, Inc., and Valirx plc.

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Shriram Dighe
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.